Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalGMED -4.83%96 EBIT per Share is $4.40 as of Mar. 2026. GuruFocus rates GMED with a GF Score™ of 96/100 and a GF Value™ of $98.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 686 Medical Devices & Instruments companies, Globus Medical ranks better than 64.14% on this metric.
Globus Medical's EBIT per Share for the
three
months ended in Mar. 2026 was $1.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.40.
During the past 12 months, the average EBIT per Share Growth Rate of Globus Medical was 112.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 19.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Globus Medical's EBIT per Share or its related term are showing as below:
GMED'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -12.3 Med: 4.4 Max: 19.4
Current: 19.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Globus Medical was 19.40% per year. The lowest was -12.30% per year. And the median was 4.40% per year.
GMED's 3-Year EBIT Growth Rate is ranked better than 64.14% of 686
companies
in the Medical Devices & Instruments industry
Industry Median: 9.25
vs GMED: 19.40
Globus Medical's EBIT for the
three
months ended in Mar. 2026 was $162 Mil.
Globus Medical (NYSE:GMED) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Globus Medical EBIT per Share Related Terms
Globus Medical EBIT per Share Historical Data
* Premium members only.
The historical data trend for Globus Medical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical (GMED) has a EBIT per Share of $4.40 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Globus Medical and its competitors. According to the industry distribution chart, Globus Medical ranks #246 out of 686 companies in the Medical Devices & Instruments industry, placing it in the top 35.9%.
Is Globus Medical's EBIT per Share too high?
Globus Medical's current EBIT per Share is $4.40. The Medical Devices & Instruments industry median EBIT per Share is 9.25. Globus Medical's value of $4.40 is 52.4% below this industry median. Based on the distribution chart, Globus Medical ranks #246 out of 686 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Globus Medical has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's EBIT per Share compare to PEN and PODD?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #246 out of 686 companies for EBIT per Share. This puts Globus Medical in the upper half of its industry. The industry median EBIT per Share is 9.25. Globus Medical's value of $4.40 is 52.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.25, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current EBIT per Share of $4.40 is 52.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current EBIT per Share is $4.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.78, compared to a current price of $77.00 — trading 22% below its estimated fair value. The current EBIT per Share is $4.40 and 52.4% below the Medical Devices & Instruments industry median of 9.25. Globus Medical's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Globus Medical (GMED), the current EBIT per Share is $4.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (GMED) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of $77.00 is trading 22% below its estimated GF Value™ of $98.78.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for GMED:
EBIT per Share: $4.40
GF Value™: $98.78 vs. price of $77.00 (22% below fair value)
Industry Position: 52.4% below the Medical Devices & Instruments median (#246 of 686)
No single metric tells the full story. See the GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
96GF Score
Get the complete analysis for GMED
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GMED has been successfully added to your 
